View Older Stories View More Recent Stories
-
UK closes in on drug pricing deal with White House - FT
-
ViiV Healthcare's Dovato matches Biktarvy efficacy with less weight gain
-
Trump: tariffs will get countries to agree to drug pricing plan
-
GSK receives FDA orphan drug designation for kidney disease treatment
-
Raymond James Reiterates Outperform Rating on Veeva Systems (VEEV) Amid 'Key Milestone'
-
Trump Posts Letters to Regeneron, Merck, AstraZeneca, GSK, Pfizer, Novo Nordisk, Amgen, Bristol-Myears, AbbVie, Novartis, Gilead, J&J on Truth Social
-
GlaxoSmithKline (GSK) Misses Q2 EPS by 71c
-
FDA extends review period for GSK's Blenrep in multiple myeloma
-
FDA approves GSK's SHINGRIX vaccine in prefilled syringe format
-
ViiV Healthcare expands licensing deal for HIV treatment access in 133 countries
-
GSK starts shipping flu vaccines for 2025-26 season to US providers
-
GSK (GSK) spreader of 5K contracts of July 11 weekly 11 puts, July 38 puts
-
GSK (GSK) announces FDA approval of 200 mg/mL autoinjector of Benlysta
-
Bernstein: 'Why Are We Bullish on GlaxoSmithKline (GSK:LN) (GSK) ?'
-
Berenberg Downgrades GlaxoSmithKline (GSK:LN) (GSK) to Hold
-
Theravance Biopharma (TBPH) Sells Remaining Royalty Interest in Trelegy Ellipta to GSK (GSK) for $225M
-
Citizens JMP: Standard of Care Modifying Regimens at ASCO 2025
-
Spero Therapeutics (SPRO) and GSK (GSK) Announce PIVOT-PO Phase 3 Study for Tebipenem HBr Stopped Early for Efficacy
-
GSK (GSK): Nucala (mepolizumab) approved by US FDA for use in adults with chronic obstructive pulmonary disease
-
GSK (GSK) receives FDA approval for Nucala COPD drug
-
GSK (GSK) to acquire efimosfermin
-
GlaxoSmithKline (GSK) Tops Q1 EPS by 18c
-
GSK Q1 earnings preview: 'Vaccines remain a drag' – Barclays
-
HSBC cuts biotech stocks: Eli Lilly lowered to Reduce
-
GSK's (GSK) 5-in-1 Meningococcal Vaccine PENMENVY Receives Positive Recommendation from US Advisory Committee on Immunization Practices
-
BNP Paribas Exane Starts GlaxoSmithKline (GSK:LN) (GSK) at Neutral
-
Pharma stocks slide after Trump signals tariffs on sector
-
GSK DEADLINE TOMORROW: ROSEN, A TOP RANKED LAW FIRM, Encourages GSK plc Investors with Losses in Excess of $100K to Secure Counsel Before Important April 7 Deadline in Securities Class Action - GSK
-
GSK DEADLINE MONDAY: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages GSK plc Investors with Losses in Excess of $100K to Secure Counsel Before Important April 7 Deadline in Securities Class Action - GSK
-
GSK DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages GSK plc Investors to Secure Counsel Before Important April 7 Deadline in Securities Class Action - GSK
-
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of GSK
-
GSK INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that GSK plc Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
-
GSK DEADLINE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages GSK plc Investors to Secure Counsel Before Important April 7 Deadline in Securities Class Action - GSK
-
Truist: 'Expect Some Pressure On Dr. Marks' Resignation'
-
GSK FINAL DEADLINE: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages GSK plc Investors to Secure Counsel Before Important April 7 Deadline in Securities Class Action - GSK
-
GSK Investors Have Opportunity to Lead GSK plc Securities Fraud Lawsuit with Faruqi & Faruqi, LLP
-
GSK IMPORTANT DEADLINE: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages GSK plc Investors to Secure Counsel Before Important April 7 Deadline in Securities Class Action - GSK
-
GSK IMPORTANT DEADLINE: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages GSK plc Investors to Secure Counsel Before Important April 7 Deadline in Securities Class Action - GSK
-
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of GSK
-
GSK DEADLINE: ROSEN, LEADING INVESTOR RIGHTS COUNSEL, Encourages GSK plc Investors to Secure Counsel Before Important April 7 Deadline in Securities Class Action - GSK
-
U.S. probing GSK's tip about timing of Pfizer (PFE) vaccine - WSJ
-
GSK INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that GSK plc Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
-
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages GSK plc Investors to Secure Counsel Before Important Deadline in Securities Class Action - GSK
-
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of GSK
-
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages GSK plc Investors to Secure Counsel Before Important Deadline in Securities Class Action - GSK
-
Faruqi & Faruqi Reminds GSK Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 7, 2025 - GSK
-
ROSEN, SKILLED NATIONAL FIRM, Encourages GSK plc Investors to Secure Counsel Before Important Deadline in Securities Class Action - GSK
-
ROSEN, A LEADING LAW FIRM, Encourages GSK plc Investors to Secure Counsel Before Important Deadline in Securities Class Action - GSK
-
GSK INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that GSK plc Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
-
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of GSK
